Compare Citius Pharmaceuticals Inc (CTXR) vs Hilton Hotels Corporation Common Stock (HLT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Hilton Hotels Corporation Common Stock — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Hilton Hotels Corporation Common Stock trades at $326 (market cap $74.18B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 5066.9× Citius Pharmaceuticals Inc's market cap, and Hilton Hotels Corporation Common Stock pays a 0.18% dividend while Citius Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| CTXR | HLT | |
|---|---|---|
Market Cap | $14.64M | $74.18B |
Sector | Health | Consumer Cyclical |
52-Week High | $1.82 | $350.22 |
52-Week Low | $0.53 | $256.75 |
Enterprise Value | $10.86M | $86.68B |
Dividend Yield | — | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
Hilton Worldwide (HLT) trades at $322.45, down 3.88% amid bearish technical signals, though it maintains strong fundamentals with consistent earnings beats and revenue growth to $12.04B in 2025. Analyst consensus remains bullish with a $340.50 price target, supported by 55% buy ratings. Recent news highlights brand campaigns and renovations, while financials show robust cash flow but rising debt levels.
The stock offers upside to analyst targets but faces near-term technical pressure and leverage concerns. Investment appeal hinges on execution of growth initiatives and debt management, with risks including economic sensitivity and competitive pressures in the hospitality sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →
